top of page
24973725_xl_normal_none_edited.jpg

Leading the Fight Against

Swine Viruses

AI-Driven Vaccine &
Antibody Development

OUR STORY

At Kermode Biotechnologies, we are dedicated to pioneering comprehensive solutions in animal health, with a focus on combating critical viral threats including African Swine Fever Virus (ASFV), Seneca Virus A, and Swine Influenza. Founded on the principles of innovation and scientific excellence, our team is developing novel vaccines that leverage unique protein antigen subunits to elicit strong immune responses in swine. With roots in both Denver, Colorado and Shenzhen, China, we bridge the gap between cutting-edge research and practical applications. Our mission is to safeguard global swine populations, enhance food security, and support farmers worldwide. Through relentless pursuit of groundbreaking research, Kermode Biotechnologies stands at the forefront of animal disease prevention, transforming challenges into opportunities for a healthier future.

AFRICAN SWINE FEVER VIRUS (ASFV)

​

The spread ASFV has devastated the commercial swine industries in Europe, Russia, and most recently China, resulting in billions of lost dollars and the loss of a major nutritional staple. It is a matter of time before ASFV infiltrates North American livestock.

Picture17.png

ASFV is a highly contagious
viral pathogen that swiftly
infects swine livestock.

Picture19.png

Once the swine are infected, the virus
will kill the animal within
24 to 48 hours.

Picture22.png

The mortality rate for
ASFV-infected animals is
100%.

SENECA VIRUS A (SVA)

​

The emergence of Seneca Virus A has disrupted swine operations across North America, causing substantial economic losses through reduced productivity and increased mortality. With its highly contagious nature, Seneca Virus A poses an escalating threat to commercial pork production, jeopardizing both industry profitability and protein security. There is currently no commercial vaccine for SVA

300

Increase in SVA detection globally between 2015 and 2024, highlighting its emerging importance as a transboundary animal disease.

Pig Virus

SVA causes open sores, blisters and negatively affects reproduction, making infected swine herds undesirable for market.

Vaccine.png

Our vaccine demonstrates nearly 100% efficacy in early challenge models, outperforming other SVA vaccines.

SWINE INFLUENZA VIRUS (SIV)

​

The emergence of Swine Influenza Virus continues to disrupt swine operations worldwide, causing substantial economic losses through reduced productivity and increased mortality. With its highly contagious nature and rapid mutation ability, SIV threatens global pork production while increasing the risk of zoonotic transmission to humans. Current vaccines struggle to keep pace with viral evolution, leaving producers vulnerable to new strains and potential pandemic threats.

Picture12.png

SIV rapidly and unpredictably mutates into new strains 

Picture13.png

Infected swine herds often experience 100% morbidity from SIV

Picture10.png

Vaccinating pigs helps prevent swine flu from jumping to humans.

OUR APPROACH

We use machine learning combined with wet biochemistry to identify weak points in how viruses reproduce and create modified versions of key viral proteins called "toxoids" that train the immune system to fight the real virus. For African Swine Fever, we use two methods: purified toxoid mixtures and a delivery system that presents multiple targets at once. Our Swine Influenza vaccine focuses on parts of the virus that are more resistant to mutation, providing broader protection against viral variants. For Senecavirus A, we use a specially weakened virus that's inherently safer due to SVA's naturally limited pathogenicity. Each approach is designed to provide strong, lasting protection while maintaining safety for livestock.

Picture35.png

TOXOID

ASFV Antibody

COMMERCIAL
DEVELOPMENT PIPELINE

Pre-Clinical

Immune Responses

Early Challenge

Late Challenge

Seneca Valley A (SVA) Vaccine

Swine Influenza Virus Vaccine

ASFV Toxoid Orf Vaccine

ASFV Toxoid Antigen Vaccine

ASFV Antibody Therapeutic

COLLABORATORS

At Kermode Biotechnologies, we believe in the power of collaboration to drive innovation and success. Our partners play a fundamental role in advancing our mission to develop cutting-edge solutions for the prevention and control of critical swine pathogens, including the African Swine Fever Virus (ASFV), Seneca Virus A (SVA), and Swine Influenza Virus (SIV). By working together, we leverage each other's strengths, expertise, and resources to accelerate the development and distribution of our groundbreaking vaccine technologies.

South Dakota Logo png.webp
Gylden Logo png.png
Komo Logo png.png
Dual Systems
Bruker

Through strategic partnerships with leading research institutions, biotechnology companies, and regulatory agencies, we are advancing innovative vaccine solutions that address these interconnected viral threats. Our collaborative approach enables us to develop synergistic strategies across multiple disease platforms while streamlining manufacturing processes for our comprehensive swine health portfolio.

KERMODE BIOTECHNOLOGIES IN THE NEWS

Newspaper

June 3rd, 2024 - Kermode to Present at the Kansas City Animal Health Corridor Summit - August 26th - 27th, 2024 

Newspapers

Feb. 4th, 2023 - Kermode Enters into Receptor Discovery Agreement with Dual Biosystems AG

Morning Newspaper

May 15th, 2021 - Former Pharma Executive, Dr. Ed Robb Joins the Kermode Executive Team as Chief of Regulatory and Veterinarian Affairs Officer

Colorado Health & Tech Centers, 5800 South Quebec St, Greenwood Village, CO

Kermode Logo Final Large 022021.png

Rights and Trademark DisclaimerTerms of Use

SOCIALS

  • Linkedin

© 2024 Kermode Biotechnologies Inc.

bottom of page